GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (NAS:MRNS) » Definitions » E10

Marinus Pharmaceuticals (Marinus Pharmaceuticals) E10 : $-4.56 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Marinus Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Marinus Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.740. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-4.56 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-29), Marinus Pharmaceuticals's current stock price is $1.425. Marinus Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $-4.56. Marinus Pharmaceuticals's Shiller PE Ratio of today is .


Marinus Pharmaceuticals E10 Historical Data

The historical data trend for Marinus Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals E10 Chart

Marinus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -4.73 -4.56

Marinus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.73 -4.76 -4.71 -4.66 -4.56

Competitive Comparison of Marinus Pharmaceuticals's E10

For the Biotechnology subindustry, Marinus Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marinus Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinus Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Marinus Pharmaceuticals's Shiller PE Ratio falls into.



Marinus Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Marinus Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.74/129.4194*129.4194
=-0.740

Current CPI (Dec. 2023) = 129.4194.

Marinus Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201403 -1.640 99.695 -2.129
201406 -1.447 100.560 -1.862
201409 -0.880 100.428 -1.134
201412 -1.030 99.070 -1.346
201503 -2.000 99.621 -2.598
201506 -1.480 100.684 -1.902
201509 -1.400 100.392 -1.805
201512 -1.840 99.792 -2.386
201603 -1.480 100.470 -1.906
201606 -1.840 101.688 -2.342
201609 -1.320 101.861 -1.677
201612 -1.240 101.863 -1.575
201703 -1.040 102.862 -1.309
201706 -0.840 103.349 -1.052
201709 -0.600 104.136 -0.746
201712 -0.800 104.011 -0.995
201803 -0.600 105.290 -0.738
201806 -0.960 106.317 -1.169
201809 -1.080 106.507 -1.312
201812 -0.960 105.998 -1.172
201903 -0.960 107.251 -1.158
201906 -0.960 108.070 -1.150
201909 -1.050 108.329 -1.254
201912 -1.020 108.420 -1.218
202003 -1.270 108.902 -1.509
202006 -0.630 108.767 -0.750
202009 -0.510 109.815 -0.601
202012 -0.550 109.897 -0.648
202103 -0.740 111.754 -0.857
202106 -0.650 114.631 -0.734
202109 -0.530 115.734 -0.593
202112 -0.770 117.630 -0.847
202203 -0.520 121.301 -0.555
202206 -1.060 125.017 -1.097
202209 1.890 125.227 1.953
202212 -0.760 125.222 -0.785
202303 -0.670 127.348 -0.681
202306 -0.610 128.729 -0.613
202309 -0.610 129.860 -0.608
202312 -0.740 129.419 -0.740

Add all the adjusted EPS together and divide 10 will get our e10.


Marinus Pharmaceuticals  (NAS:MRNS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Marinus Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Marinus Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Marinus Pharmaceuticals (Marinus Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Executives
Christina Shafer officer: Chief Commercial Officer 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD ROAD, RADNOR PA 19087
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Steven Pfanstiel officer: CFO 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Joseph Hulihan officer: Chief Medical Officer 5 RADNOR CORP CENTER SUITE 500, 100 MATSONFORD RD, RADNOR PA 19087
Martha E Manning officer: VP, Gen. Counsel & Corp. Sec. 700 PENNSYLVANIA DR, EXTON PA 19341
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Marvin Johnson director C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Elan Ezickson director AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Charles Austin director 5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Christine Berni Silverstein director C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Santiago Arroyo director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Sara Nochur director 295 WOODCLIFF RD, NEWTON MA 02461
Nicole Vitullo director, 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Edward F Smith officer: Chief Financial Officer C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104

Marinus Pharmaceuticals (Marinus Pharmaceuticals) Headlines